SNDX

$0.00

(

+0.00%

)
Quote details

stock

Syndax Pharmaceuticals Inc

NASDAQ | SNDX

17.18

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 17, 2025)

$1.45B

Market Cap

-

P/E Ratio

-3.6

EPS

$18.00

52 Week High

$8.58

52 Week Low

HEALTHCARE

Sector

SNDX Chart

Recent Chart
Price Action

SNDX Technicals

Tags:

SNDX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $23M
Total Revenue $24M
Cost Of Revenue $826K
Costof Goods And Services Sold $826K
Operating Income -$340M
Selling General And Administrative $121M
Research And Development $242M
Operating Expenses $363M
Investment Income Net -
Net Interest Income $21M
Interest Income $26M
Interest Expense $4.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $8K
Income Before Tax -$319M
Income Tax Expense -$319M
Interest And Debt Expense -
Net Income From Continuing Operations -$319M
Comprehensive Income Net Of Tax -
Ebit -$314M
Ebitda -$314M
Net Income -$319M

Revenue & Profitability

Earnings Performance

SNDX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $725M
Total Current Assets $603M
Cash And Cash Equivalents At Carrying Value $154M
Cash And Short Term Investments $154M
Inventory $366K
Current Net Receivables $14M
Total Non Current Assets $122M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $120M
Short Term Investments $429M
Other Current Assets $5.9M
Other Non Current Assets -
Total Liabilities $437M
Total Current Liabilities $104M
Current Accounts Payable $12M
Deferred Revenue -
Current Debt -
Short Term Debt $13M
Total Non Current Liabilities $333M
Capital Lease Obligations $2.1M
Long Term Debt $332M
Current Long Term Debt $12M
Long Term Debt Noncurrent -
Short Long Term Debt Total $346M
Other Current Liabilities $79M
Other Non Current Liabilities -
Total Shareholder Equity $288M
Treasury Stock -
Retained Earnings -$1.2B
Common Stock $9K
Common Stock Shares Outstanding $86M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$275M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $8K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -$366K
Profit Loss -
Cashflow From Investment -$220M
Cashflow From Financing $353M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$319M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $23M
Total Revenue $24M
Cost Of Revenue $826K
Costof Goods And Services Sold $826K
Operating Income -$340M
Selling General And Administrative $121M
Research And Development $242M
Operating Expenses $363M
Investment Income Net -
Net Interest Income $21M
Interest Income $26M
Interest Expense $4.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $8K
Income Before Tax -$319M
Income Tax Expense -$319M
Interest And Debt Expense -
Net Income From Continuing Operations -$319M
Comprehensive Income Net Of Tax -
Ebit -$314M
Ebitda -$314M
Net Income -$319M

SNDX News

SNDX Profile

Syndax Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies for the treatment of cancer. The company's robust pipeline includes novel agents designed to address significant unmet medical needs in various malignancies, leveraging both immuno-oncology and epigenetic modulation strategies. Syndax is committed to advancing its clinical programs to improve outcomes for patients facing challenging cancer diagnoses, positioning itself as a key player in the evolving landscape of cancer therapeutics.

WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
PLUG
-7.12%
$2.08
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
AAL
-3.29%
$12.34
RGTI
-3.10%
$24.69
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
BTBT
-4.56%
$2.30
HBAN
-2.73%
$15.30
HIMS
-3.78%
$35.58
MU
-1.97%
$241.95
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
SMR
-6.19%
$21.06
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
NBIS
+2.92%
$85.98
JOBY
-3.60%
$13.89
WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
PLUG
-7.12%
$2.08
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
AAL
-3.29%
$12.34
RGTI
-3.10%
$24.69
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
BTBT
-4.56%
$2.30
HBAN
-2.73%
$15.30
HIMS
-3.78%
$35.58
MU
-1.97%
$241.95
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
SMR
-6.19%
$21.06
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
NBIS
+2.92%
$85.98
JOBY
-3.60%
$13.89

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.